600 patients67,035 observations120 daysLIVE

Patient P-01464

Synthetic patientNBL-101 · Day 116 · 75+ · F · baseline S05Steering view · 3DOpen companion preview
Is the drug working?

Therapy response 69 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 79%, therapy response 76 today; biology is not blocking the drug.

Is a side effect starting?

No side effect starting: gi toxicity 12, systemic toxicity 13, no drift from the model.

Still taking it?

8 of 9 scheduled doses in the last 60 days are biologically confirmed (89%); 1 were logged but show no dose signature. Dose signature: resting HR +6 bpm, HRV −10 ms.

last 9 doses · green confirmed · amber logged only · red missed
Plan for this patient
stable, no actionrecommendowner · Companionreview day 123Human Model →
Next action
No action indicated; maintain.
Kept if

Trajectory is stable relative to similar patients; keep the current content.

Daily to-dos in the companion
  • 🍽Keep meals regular; three to four moderate portions spaced through the day
  • 🍽Include a cooked vegetable portion with each main meal
  • Log the daily check-in; one line is enough
  • Keep the current walking rhythm
  • 💊Take the scheduled dose as agreed with your care team
  • 💊No additional supplements this week
Adherence
92% improving

Adherence is not the problem.

Changes the plan if

sleep quality falling under 35 while GI rises

LLIFE OS insight
grounded · add an LLM key for prose

P-01464 is on day 116 of NBL-101 (SR, baseline S05): response declining, tolerance deteriorating, GI improving. Over 14 days response moved -9 and GI -6; discontinuation risk is 8%. The state is in the restoration basin, heading towards failing.

Butyrate capacity 64/100, diversity 3.5, normal metabolizer. Pushing it down: Escherichia coli 10.608% (LPS load) (-27.1), Bacteroides fragilis elevated (-11.9), Antibiotic course (-4.7). Pulling it up: Butyrate producers intact (+12.1), Daily walks resumed (+3.3).

No action has been tried yet.

No action is indicated now; the trajectory is stable relative to similar patients.

Therapy response
Declining
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Deteriorating
Nutritional resilience
Favorable
Discontinuation risk
8%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (weekly infusion, day 1 of each 7-day cycle)
  1. Day 0 NBL-101 startedBaseline state S05

What changed?

Trajectory is tracking the baseline prediction.

Primary contributors, last 14 days
  • Inflammatory activity+9
  • GI instability-6
  • Toxicity+5
  • Nutritional resilience+2
  • Treatment adherence+2

What helped?

No interventions yet.

    LIFE OS recommendation
    No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

    Daily trackers

    Asset settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    GI burden
    Companion
    11.8/100
    stable · +0.3 vs previous 14 d
    Toxicity
    Blood
    13.3/100
    improving · -2.8 vs previous 14 d
    Sleep quality
    Wearable
    36.5/100
    worsening · -3.3 vs previous 14 d
    Energy level
    Daily log
    6.1/10
    stable · +0.2 vs previous 14 d
    Stress level
    Daily log
    3.8/10
    stable · +0.0 vs previous 14 d
    Steps
    Wearable
    5,001
    stable · -211 vs previous 14 d
    Adherence
    Companion
    92.3 %
    improving · +4.6 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards failing · 87 from the failing basin, 8 from restoration.

    Would help
    • No untried action with strong evidence. Compose one from primitives.
    Would not help
    • Nothing clearly counter-productive in the record.
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Simple carbohydrates
      -2.3no signal · 36%
    • Dietary fat load
      +1.8no signal · 43%
    • Alcohol
      +1.7no signal · 35%
    • Insoluble fibre
      +1.5no signal · 31%
    • Spicy / capsaicin
      -0.8no signal · 15%
    • Histamine load
      -0.7no signal · 15%

    DeepGene damage signature

    The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

    Damage score · retest day 90
    40/100
    vs baseline (day 0)
    +23
    1 improved · 7 worsened
    synthetic signature · consistent with this patient's biology
    • 3 opportunists above range: Escherichia coli, Klebsiella pneumoniae, Clostridioides difficile
    • 2 keystone species absent
    • Shannon 2.94 (expected ≥ 3)
    • 4 resistance genes
    Pathogens / opportunists3/5
    from 0
    Keystone species2/8
    from 1
    Diversity1/2
    from 0
    Metabolic modules0/4
    Vitamin synthesis2/7
    from 1
    Oral translocation1/1
    Host DNA0/1
    Tissue recycling0/1
    Central mechanisms0/2
    Virulence factors2/2
    from 1
    Antibiotic resistance genes4/4
    from 5
    Genetic predisposition1/1
    Opportunists above range
    Escherichia coli 10.608% AR
    Klebsiella pneumoniae 3.182% AR
    Clostridioides difficile 1.061% AR
    Keystone species absent
    Akkermansia muciniphila, Bifidobacterium longum
    Capacity
    Shannon 2.94 · butyrate 741 CPM · SCFA 1202
    2 vitamins below
    Host & mechanisms
    tissue recycling 30/100
    oral translocation 2.44% AR
    4 resistance genes · 2 virulence factors

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Autonomic recovery 45
      • WearableResting HR 75 bpm
      • WearableShort sleep window
    • Mucosal barrier integrity 40
      • MicrobiomeAkkermansia low → thinner mucus layer
      • WearableSleep 5.8 h, below personal baseline
    • Inflammatory signalling 20
      • MicrobiomeBacteroides fragilis expansion
    DNA
    Fictional pharmacogenomic panel
    • CYP2D6 Normal metabolizer
      Expected exposure
    Microbiome
    Shannon diversity 3.5 · butyrate capacity 64/100
    • Akkermansia muciniphilaLow
    • Faecalibacterium prausnitziiNormal
    • Bacteroides fragilisHigh
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeNormal
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    47 ms
    Sleep
    6.1 h
    Steps
    6,103
    Resting HR
    74 bpm
    Daily log: GI score 12, nutritional resilience 66, adherence 92.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Keep meals regular; three to four moderate portions spaced through the day
    • Include a cooked vegetable portion with each main meal
    • Keep fibre steady; no new sources this week
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Log the daily check-in; one line is enough
    • Keep the current walking rhythm
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • No additional supplements this week
    • Fictional demo item: continue vitamin D as before

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0155849%S0187
    P-0143547%S0174
    P-0176643%S01BR-03improved83
    P-0176342%S0185
    P-0164840%S0186
    P-0145636%S0188
    P-0152631%S0165
    P-0168427%S0164
    P-0174827%S0167
    P-0162250%S0286
    P-0167245%S0284
    P-0167344%S0276